

# Subject Index

## A

Acivicine 73  
Activation; T-cell 157–161  
Active, specific  
  immunotherapy 142–147,  
  189–199, 212–219  
Adhesion molecules 101–101  
Adjuvants 189  
Adoptive immunotherapy 181  
Adriamycin see Doxorubicin  
Alanosine 73  
Alien gene 134–141  
Aminothiadiazole 73  
Amonafide 73  
Amsacrine 73  
Analysis DNA Sequences 27–37  
Anthracyclines 73, 74  
Antibody, bispecific  
  monoclonal 157–161  
Antifols 73  
Antigen MHC-, Induction 121  
Antiproliferative, effects 117, 125  
  – of interferon 125  
Antitumor, effects 117, 125  
  – of interferon 125  
Autocrine stimulation

## B

BCG 212, 168  
Bisantrene 73  
Bispecific, monoclonal  
  antibody 157–161

## C

Carboplatin 73  
Carcinogenesis 9

Chemotherapy cytotoxic 71  
Chromosome 3  
  – deletion 4, 30  
  – insertion 31  
  – markers 31  
  – translocation 4  
Chromosome 7 trisomy 5  
Chromosome 17 trisomy 5  
Chromosome loss 5  
Clear cell tubules 17  
Clear cell tumors 17  
Collagenase 214  
Cyclophosphamide 73, 75

## D

Daunomycin 93  
10-Deaza-aminopterin 73  
Deoxycytidine 73  
Diaziquone 73  
Diltiazem 81  
Doxorubicin 93

## E

Elliptinium 73  
Epirubicin 73  
Esorubicin 73  
Etoposide 73

## F

Familial renal cell carcinoma 4, 31  
  – von Hippel-Lindau disease 4, 31  
Fludarabine 73, 76  
5-Fluorouracil 91  
Fluoroxidine 73

**G**

- Galliumnitrate 73
- Gamma-Glutamyl-transferase 148
- Gamma-Glutamyl-transferase  
  Monoclonal Antibody 148–155
- Gene transfer 183
- Gene, therapy 165, 183
- Glycoprotein 115

**H**

- HAMA, see Human antimouse antibodies
- HLA, see Human Leukocyte Antigen
- Hormonal therapy 76
- Human antimouse antibodies
- Human Leukocyte Antigen
  - class I 115, 130–132, 171
  - class II 115, 132

**I**

- ICRF 187
- IFN, see Interferon
- Ifosfamide 73
- IL-1, see Interleukin-2
- IL-2, see Interleukin
- Immunosurveillance 193, 101–114
- Immunotherapy
  - active 142–147, 189–199, 212–219
  - adoptive 181
- Inhalation 221
- Inhalation, Interleukin-2 221–233
- Interferon
  - alpha, clinical trials 213–218
  - experimental studies 43, 116–120, 122–125
  - side effects 218
- Interferon Gamma 108, 125, 173
- Interleukins
- Interleukin-1 194–198
- Interleukin-2 clinical trials 192, 207–209, 212–218, 222–233
  - experimental studies 166–185, 190–194
  - side effects 218, 228, 232
- Interleukin-2 receptor 175
- Interleukin 4 109, 204

**K**

- K-cells, see Killer cells
- Killer cells 101–114

**L**

- LAK cells, see Lymphokine-Activated Killer cells
- Lymphocytes
  - in vitro sensitized 166–185
  - peripheral blood
  - subsets 167, 204, 157
  - T- 167, 204–205
- Lymphokine-Activated Killer cells
  - clinical trials 170
  - experimental studies 166–179
  - side effects
- Lysis of RCC 205

**M**

- MAB, see Monoclonal antibody
- Major Histocompatibility Complex 172
- MDR, see multiple drug resistance
- Menogaril 73
- Methotrexate (MTX) 91
- MHC see Major Histocompatibility Complex
- Mice, athymic or nude 122
- Mice, transgenic 89–100, 186–187
- Mitolactol 73
- Modulation, drug resistance 79–100
- Monoclonal antibody
  - mAB Ki67 62
  - mAb F33 117
  - mAb S22 117
  - mAb F23 117
  - mAb F31 117
  - mAb 138 H 11 148–155
  - mAb T 43 117
  - bispecific 157–159
- Multiple drug resistance 79
  - MDR1 gene 89

**N**

- Natural killer cells 77, 101
- Nifedipine (NIF) 80
- Nimodipine (NIM) 80
- Nitrendipine (NIT) 80

NK cells, see Natural killer cells  
 Non-hereditary renal cancer 28  
 Non-papillary renal cancer 29

**O**

Oncocytic tubules 20  
 Oncocytoma 20  
 Oncogenes 186

**P**

Pathobiology 9–26  
 Pathology, molecular,  
   differential 3–8  
<sup>31</sup>P Spectroscopy 37–48  
 P170, see P-glycoprotein  
 PBL, see Lymphocytes, peripheral  
   blood  
 P-glycoprotein 80, 85, 86  
 Prediction, cytokine-therapy 115  
 Proliferation rate 61–67

**R**

Rat renal cancer 15  
 Renal subcapsule implantation 44  
 Renca adenocarcinoma  
 Restriction fragment length  
   polymorphism 28  
 R-Verapamil (R-VPM) 80, 81, 83

**S**

Sparfosc acid 73  
 Spirogermanium 73  
 Surgery  
   – complications 49–60  
   – conservative 49–60

– operative technique 49–60  
 – results 49–60  
 Streptozotocin 15, 73

**T**

Taxol 73  
 Teniposide 73  
 THP ADM 73  
 Thymus-cell growth factor 166  
 Triepoxide 73  
 Trimetotrexate 73  
 Tumor infiltrating  
   lymphocytes 170–171, 200–209  
   – lytic activity 205  
   – state of activation 206–207  
   – toxicity 208  
 Tumor necrosis factor alpha  
   – clinical trials 180  
   – experimental studies 48, 122, 175  
   – side effects 180  
 Tumor suppressor gene 30

**V**

Vaccination 142, 212  
 Vaccine, tumor  
   – allogeneic 142–147  
   – autologous 212–219  
 Verapamil 81  
 Vinblastine 73  
   – side effects 93  
 VP-16, see Etoposide

**X**

Xenograft 44, 118, 122